Cobalamin used in chronic fatigue syndrome therapy is a nitric oxide scavenger

Journal of Chronic Fatigue Syndrome

Volumn 8, Issue 2, 2001, Pages 39-44

  Pall, M L ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Antioxidant; Oxidative stress; Peroxynitrite; Reactive nitrogen species; Therapeutic agents; Vicious cycle mechanism; Vitamin B12

Indexed keywords

ANTIOXIDANT; COBALAMIN; NITRIC OXIDE; PEROXYNITRITE;

ANTIOXIDANT ACTIVITY; CHRONIC FATIGUE SYNDROME; DRUG EFFICACY; HUMAN; OXIDATIVE STRESS; REVIEW; TREATMENT OUTCOME;

EID: 0035200699     PISSN: 10573321     EISSN: None     Source Type: Journal    
DOI: 10.1300/J092v08n02_04     Document Type: Review

References (38)

1. Treatment of patients with chronic fatigue syndrome
2. Using vitamin B- 12 for the management of CFS
3. Treatment at the Cheney clinic
4. 12, chronic fatigue and injection treatment
5. N of I trials. Managing patients with chronic fatigue syndrome: Two case reports
6. Elevated peroxynitrite as the cause of chronic fatigue syndrome
7. Elevated peroxynitrite as the cause of chronic fatigue syndrome: Other inducers and mechanisms of symptom generation
8. Tetrahydrobiopterin and cytokines
9. Biochemistry and function of pteridine synthesis in human and murine macrophages
10. Serum neopterin and interleukin-6 levels in chronic fatigue syndrome
11. Serum concentrations of 2′,5′-oligoadenylate synthetase, neopterin, and beta-glucan in patients with chronic fatigue syndrome and in patients with major depression
12. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: Interrelations with cellular sources and patterns of soluble immune mediator expression
13. Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome
14. Markers of inflammation and immune activation in chronic fatigue syndrome
15. Altered cytokine release in peripheral blood mononuclear cell cultures from patients with chronic fatigue syndrome
16. Cytokine production by adherent and non-adherent mononuclear cells in chronic fatigue syndrome
17. Interleukin-113, interleukin-1β receptor antagonist and soluble interleukin-I receptor type II secretion in chronic fatigue syndrome
18. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: Role of sleep disturbance and obesity
19. Acute phase responses and cytokine secretion in chronic fatigue syndrome
20. Chronic fatigue syndrome: Identification of distinct subgroups on the basis of allergy and psychologic variables
21. Cytokine dysregulation in the post-Q-fever fatigue syndrome
22. TNF a and chronic fatigue syndrome
23. Interactions between hydroxocobalamin and nitric oxide (NO): Evidence for a redox reaction between NO and reduced cobalamin and reversible NO binding to oxidized cobalamin
24. Differential effects of hydroxocobalamin in NO-medicated relaxations of rat aorta and anococcygeus muscle
25. Hydroxocobalamin (vitamin Bl2a) prevents and reverses endotoxin-induced hypotension in rodents: Role of nitric oxide
26. Interaction of heme oxygenase-2 with nitric oxide donors: Is the oxygenase an intracellular "sink" for NO?
27. Thiol compounds interact with nitric oxide in regulating heme oxygenase-1 induction in endothelial cells. Involvement of superoxide and peroxynitrite anions
28. Cobalamin coenzyme synthesis in normal and mutant human fibroblasts: Evidence for a processing enzyme activity deficient in cbl C cells
29. Increased concentration of homocysteine in the cerebrospinal fluid in patients with chronic fatigue syndrome and fibromylagia
30. The inactivation of methionine synthase in isolated rat hepatocytes by sodium nitroprusside
31. "Anesthesia paresthetica": Nitrous oxide-induced cobalamin deficiency
32. Co-ordinate variations in methylmalonyl-CoA mutase and methionine synthase, and the cobalamin cofactors in human glioma cells during nitrous oxide exposure during nitrous oxide exposure and subsequent recovery phase
33. Nitrous oxide anesthesia-associated myelopathy
34. 12 XVI. Modification of cyanocobalamin
35. Pernicious anemia. Early identification to prevent permanent sequelae
36. Neurologic and evoked potential abnormalities in subtle cobalamin deficiency states, including deficiency without anemia and with normal absorption of cobalamin
37. The chronic fatigue syndrome: A comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group